These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20446791)

  • 1. Protective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats.
    Kanter M; Sen S; Donmez S; Aktas C; Ustundag S; Erboga M
    Ren Fail; 2010 May; 32(4):498-505. PubMed ID: 20446791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
    Sen S; Kanter M; Ustundag S; Aktas C; Dogutan H; Yalcin O
    Ren Fail; 2008; 30(10):1023-33. PubMed ID: 19016156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of irbesartan on renal hypertrophy and thickening of glomerular basement-membrane in streptozotocin-induced diabetic rats].
    Liu BC; Luo DD; Sun J; Ma KL; Ruan XZ
    Zhonghua Nei Ke Za Zhi; 2003 May; 42(5):320-3. PubMed ID: 12882713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of thymoquinone on streptozotocin-induced diabetic nephropathy.
    Kanter M
    J Mol Histol; 2009 Apr; 40(2):107-15. PubMed ID: 19484499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats.
    Liu BC; Chen Q; Luo DD; Sun J; Phillips AO; Ruan XZ; Liu NF
    Acta Pharmacol Sin; 2003 Jan; 24(1):67-73. PubMed ID: 12511232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
    Anjaneyulu M; Chopra K
    Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
    Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
    Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
    Ren X; Guan G; Liu G; Liu G
    Pharmacology; 2009; 83(2):80-7. PubMed ID: 19065061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Extract of Ginkgo biloba and alpha-lipoic acid attenuate advanced glycation end products accumulation and RAGE expression in diabetic nephropathy rats].
    Li XZ; Yan HD; Wang J
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Apr; 31(4):525-31. PubMed ID: 21608227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy.
    Tunçdemir M; Oztürk M
    Acta Histochem; 2011 Dec; 113(8):826-32. PubMed ID: 21269661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of selective cyclooxygenase -2 inhibitor on the renal lesion of streptozotocin-induced diabetic rats and its possible mechanism].
    Zuo Y; Gu Y; Ma J; Lin S
    Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(4):239-43. PubMed ID: 11953170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
    Hofni A; El-Moselhy MA; Taye A; Khalifa MM
    Eur J Pharmacol; 2014 Dec; 744():173-82. PubMed ID: 25446917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
    Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
    Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
    Vieitez P; Gómez O; Uceda ER; Vera ME; Molina-Holgado E
    J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):96-102. PubMed ID: 18584585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid.
    Mao ZM; Shen SM; Wan YG; Sun W; Chen HL; Huang MM; Yang JJ; Wu W; Tang HT; Tang RM
    J Ethnopharmacol; 2015 Sep; 173():256-65. PubMed ID: 26226437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the Ku70 and apoptosis-related proteins in experimental diabetic nephropathy.
    Tunçdemir M; Öztürk M
    Metabolism; 2016 Oct; 65(10):1466-77. PubMed ID: 27621182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on pyrazinoylguanidine. 5. Temporal effects over 24 weeks demonstrating attenuation of diabetic nephropathy in STZ-diabetic rats.
    Follansbee MH; Beyer KH; Griffith JW; Vesell ES
    Pharmacology; 1997 May; 54(5):241-55. PubMed ID: 9380770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
    Kakizawa H; Itoh Y; Imamura S; Matsumoto T; Ishiwata Y; Ono Y; Yamamoto K; Kato T; Hayakawa N; Oda N; Goto Y; Goto Y; Nagasaka A; Senda T; Itoh M
    Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ameliorative effect of Metformin / alpha-lipoic acid combination on diabetic nephropathy via modulation of YAP/ miR-29a/PTEN/p-AKT axis.
    Helmy SA; Nour OA; G Abd El Salam AS
    Int Immunopharmacol; 2024 Jun; 135():112294. PubMed ID: 38776856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of angiotensin II receptor antagonist on rat podocyte injury in early diabetic nephropathy].
    Long HB; Zhong J; Wei LB; Zhou WD; Xu ZZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Apr; 27(4):505-8. PubMed ID: 17545045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.